ABSTRACT
Background SARS-CoV2 has evolved to enter the host via the ACE2 receptor which is part of the Kinin-kallirein pathway. This complex pathway is only poorly understood in context of immune regulation but critical to control infection. This study examines SARS-CoV2 infection and epithelial mechanisms of the kinin-kallikrein system at the kinin B2 receptor level in SARS-CoV-2 infection that is of direct translational relevance.
Methods From acute SARS-CoV-2-positive patients and -negative controls, transcriptomes of nasal brushings were analyzed. Primary airway epithelial cells (NHBEs) were infected with SARS-CoV-2 and treated with the approved B2R antagonist icatibant. SARS-CoV-2 RNA RT-qPCR, cytotoxicity assays, plaque assays and transcriptome analyses were performed. The treatment effect was further studied in a murine airway inflammation model in vivo.
Results Here, we report a broad and strong upregulation of kallikreins and the kinin B2 receptor (B2R) in the nasal mucosa of acutely symptomatic SARS-CoV-2-positive patients. A B2R antagonist impeded SARS-CoV-2 replication and spread in NHBEs, as determined in plaque assays on Vero E6 cells. B2R antagonism reduced the expression of SARS-CoV-2 entry receptor ACE2 in vitro and in a murine airway inflammation model in vivo. In addition, it suppressed gene expression broadly, particularly genes involved in G-protein-coupled-receptor signaling and ion transport.
Conclusions In summary, this study provides evidence that treatment with B2R antagonists protects airway epithelial cells from SARS-CoV-2 by inhibiting its replication and spread, through the reduction of ACE2 levels and the interference with several cellular signaling processes. Future clinical studies need to shed light on the airway protection potential of approved B2R antagonists, like icatibant, in the treatment of early-stage COVID-19.
1 INTRODUCTION
SARS-CoV-2 vaccines have been approved worldwide since the end of 2020 and are starting to show their protective effects in public health.1,2 Even with vaccines at hand, an important medical need for therapeutic approaches for COVID-19 remains: Parts of the population refrain from vaccination or are not eligible for it, immunocompromised individuals may not mount a sufficient immune response after vaccination and escape variants, such as the currently spreading SARS-CoV-2 variant Delta3, may breach the protection afforded by the vaccines.4-9 Key factors for SARS-CoV-2 cell entry are two cell surface molecules, the angiotensin-converting enzyme 2 (ACE2) and the transmembrane serine protease (TMPRSS)2.10 TMPRSS2 cleaves the coronaviral spike protein and primes it for cell fusion, while ACE2 enables the virus particle to enter the cell by binding of its spike protein.11,12 The latter acts as central component in its function as terminal carboxypeptidase in the counter-regulatory axis of the renin-angiotensin system (RAS) and the contact activation system (CAS),10,13 which initiates blood coagulation and can additionally activate the kinin-kallikrein system (KKS).14 In its role in the RAS, ACE2 has anti-vasoconstrictive and anti-inflammatory effects by hydrolyzing the vasoconstrictive and tissue-damaging angiotensin II, which contributes to airway remodeling and fibrosis,15,16 to angiotensin (1-7).17 In its role in the KKS, ACE2 further hydrolyzes vasoactive peptides such as des-Arg9-bradykinin (DABK), which activates the inflammatory axis of the KKS.18,19 While DABK is the ligand of the inducible kinin B1 receptor (BDKRB1; B1 receptor),20 bradykinin, the end product of the KKS cascade, binds to the constitutively expressed kinin B2 receptor (BDKRB2; B2 receptor; B2R) and activates it.21 Bradykinin mediates its pro-inflammatory effects via the B2 receptor, by eliciting a variety of responses, including vasodilation and edema, via the G protein-triggered phosphatidylinositol-calcium second messenger system.22-26
The fact that SARS-CoV-2 utilizes ACE2 to enter airway cells along with the fact that ACE2 is a multifunctional enzyme that counter-regulates the ACE-driven mechanisms of the RAS and balances the KKS, may therefore explain the serious course of COVID-19, not only in the lungs but systemically.27,28
Recent publications suggest that the KKS could play a role in COVID-19. KKS comes into play particularly in connection with the high prevalence of thromboembolic events in seriously ill COVID-19 patients.7,18,20,29,30 A recent study on a cohort of 66 COVID-19 patients admitted to the intensive care unit showed that the KKS was strongly activated, which was reflected in the consumption of factor XII, pre-kallikrein and high-molecular-weight kininogen (HMW-kininogen).29 It has further been hypothesized that kinin-dependent “local lung angioedema” involving the kinin B1 and B2 receptors is an important characteristic of COVID-19.31-34
This study examines the potential of interfering with the KKS at the kinin receptor level in SARS-CoV-2 infection with translational relevance. Based on a broad and strong upregulation of kallikreins and of the kinin B2 receptor in the nasal mucosa of acutely SARS-CoV-2-positive patients, we hypothesized that the B2 receptor antagonism using icatibant, an approved compound for the treatment of hereditary angioedema,35 had an early protective effect against SARS-CoV-2-mediated epithelial damage through disruption of ACE2-mediated virus entry.
2 MATERIALS AND METHODS
2.1 Patients and nasal brushings
The nasal brushings were performed as a part of a larger health professional observational cohort study, which was approved by the ethics commission of the Technical University of Munich (AZ 175/20s). Nasal brushings were subjected to whole-genome microarray transcriptome analysis (see Supp.Info.). All patients gave written, informed consent prior to participation (see Table 1).
2.2 In vivo mouse study
Mice received murine IL-12Fc (1 μg of protein in 50 μL PBS) or PBS control intranasally.36 Intranasal application was performed under isoflurane anesthesia in two steps of 25 μL per nostril. 48 hours later, the mice received a single subcutaneous injection of icatibant (2 nmol per 10 g body weight; HOE-140 (icatibant), H157, SLBX4410, Sigma) or PBS control. The experiment was terminated by CO2 asphyxiation 6 hours or 24 hours after the injection of icatibant. The experiment was carried out twice Organs were snap frozen for protein extraction. Mice enrolled in the experiment were 6-8 weeks old, from either C57BL/6J, BALB/c or C3H HeN strains. Both sexes were included for each strain and means of each mouse type (strain / sex) are depicted as single values in Fig.2A: circle: female; triangle: male. Black: C57BL/6, mid grey: C3H HeN, light grey: BALB/c strain. Experiments were performed and analyzed in a randomized and blinded fashion. Animals were obtained from Janvier Labs (Le Genest-Saint-Isle, France) and housed 5 per cage and sex in individually ventilated cages at Laboratory Animal Service Center of the University of Zurich in Schlieren (Schlieren, Zurich, Switzerland). The animal vivarium was a specific-pathogen-free (SPF) holding room, that was temperature- and humidity-controlled (21 ± 3 °C, 50 ± 10%), with a 12h light/dark cycle. All animals had ad libitum access to the same food and water throughout the entire study. All procedures described in this study had previously been approved by the Cantonal Veterinarian’s Office of Zurich, Switzerland (License ZH096/20), and every effort was made to minimize the number of animals used and their suffering. Experiments were pre-registered at www.animalstudyregistry.org (study title “Effect of drug on ACE2 levels in mice”; doi=10.17590/asr.0000225).
Detailed methods are provided in the online supporting information.
3 RESULTS
3.1 B2 receptor antagonist inhibits replication and spread of SARS-CoV-2
The enzyme ACE2 is the central viral entry receptor for the novel SARS-CoV-2 coronavirus on human epithelial cells of the respiratory tract.10 Recent studies showed that this receptor and its co-receptors are not only expressed in the lower respiratory tract, and thus on the alveolar epithelial cells type I and II, but are also present in the upper respiratory tract, but are predominantly expressed in the nasal mucosa.37
To investigate the local effect of the acute SARS-CoV-2 infection on the nasal epithelium, we analyzed the transcriptome of nasal brushings from symptomatic patients who tested acutely positive for SARS-CoV-2 and of SARS-CoV-2-negative patients. In a transcriptome analysis, the most strongly induced genes encoding secreted factors included many members of the kallikrein family (Fig.1A, Table S1). In particular, the kallikreins KLK5, KLK9 and KLK12 were significantly upregulated in acute SARS-CoV-2-positive patients compared to SARS-CoV-2-negative patients (Fig.1B, Table S2). A subsequent analysis focusing on central factors of the KKS revealed that in addition, the kinin receptor B2 (BDKRB2; B2R) was also significantly increased (Fig.1C, Table S3). This first finding, together with our hypothesis that ACE2, as a central component, is counter-regulated by intervention in the KKS, prompted us to investigate selective kinin B2 receptor antagonism in connection with SARS-CoV-2 infection. To circumvent the limitations of cell lines like Vero E6, A549 or Calu-3 cells that are intrinsically impaired to form an interferon response upon viral infection,38 we next infected primary bronchial epithelial (NHBE) cells with SARS-CoV-2.
To examine the effects of SARS-CoV-2 infection and B2R antagonist treatment on the microscopic integrity of the airway epithelium, 3D-air-liquid interphase organoid cultures were differentiated from primary NHBEs (see Supp.Info). After complete differentiation, the epithelia were pre-treated from the basal (medium) side with the approved B2R antagonist icatibant, and subsequently infected with SARS-CoV-2 from the apical (air) side. The cultures pre-treated with the B2R antagonist showed less virus-induced balloon-like structures compared to untreated cultures. The epithelial layers remained qualitatively more intact, which indicated a protective effect of the B2R antagonist for the bronchial epithelium (Fig.1D). This finding was further strengthened by cytotoxicity assays: The B2R antagonist had no toxic effects on NHBEs even at high doses determined by lactate dehydrogenase (LDH) release, but rather exhibited a cell-protecting effect in uninfected cells (Fig.1E) as well as during SARS-CoV-2 infection (Fig.1F). Next, the supernatants of pre-treated, infected primary NHBEs were collected, titrated onto fresh Vero E6 cell cultures and plaque assays were performed. Strikingly, we found that in vitro treatment of NHBEs with the B2R antagonist prior to infection reduced the number of plaque forming units (PFU) in a plaque assay by 87% (Fig.1G). In addition, the levels of total SARS-CoV-2 RNA in cells that had been pretreated with the B2R antagonist decreased by 52% compared to untreated infected NHBEs (Fig.1H). With regard to the virus entry process, ACE2 was reduced by pretreatment with the B2R antagonist on the mRNA level (Fig. 1I) and on the protein level (Fig. 1J). The membrane-standing protease TMPRSS2 cleaves the spike protein for SARS-CoV-2 and primes it therefore for optimized binding to its entry receptor ACE2. In contrast to ACE2, the TMPRSS2 transcript levels were significantly increased in infected compared to uninfected NHBEs but were not affected by B2R antagonist pre-treatment (Fig.S2A). Further experiments on the effect of the B2R antagonist on the SARS-CoV-2 infection of NHBE showed that pre-treatment with the B2R antagonist significantly reduced infection-mediated cytotoxicity measured by LDH release (Fig.1F).
3.2 Repetitive treatment with B2R antagonist inhibits SARS-CoV-2 replication and spread post-infection
The finding that B2R antagonism leads to a downregulation of ACE2 protein levels in lung epithelial cells was confirmed in vivo in a murine airway inflammation model. 24 sex-matched mice from three different strains per group were treated in two blocks intranasally with murine IL-12Fc to mimic virus-induced airway inflammation via activation of the IL-12 / IFN-γ axis.36 After 48 hours, mice were injected subcutaneously (s.c.) with the B2R antagonist and the experiment was terminated six hours or 24 hours later. IL-12Fc-pretreated mice, which were then further treated with the B2R antagonist on day 2, had significantly reduced ACE2 protein levels in the lungs after six hours compared to control mice, which were only treated with PBS on day 2 (Fig.2A). This effect decreased after 24 hours.
Anticipating treatment of SARS-CoV-2 infected patients with the B2R antagonist icatibant, NHBEs were first infected with SARS-CoV-2 and then treated with the B2R antagonist six hours after infection. Confirming the results of the pre-treatment, post-infection treatment with the B2R antagonist also attenuated the cytopathic effect of SARS-CoV-2 (Fig.2B) and reduced the number of PFU in a plaque assay on Vero E6 cells by 84% (Fig.2C).
We also aimed to reflect pharmacokinetics39 during treatment of early infection by treating NHBEs post-infection every 24 hours with the B2R antagonist repeatedly for a period of 96 hours, reflecting the drug administration of this particular substance in real life. In cells treated post-infection with 100 nM icatibant for 48 hours, the total viral RNA (Fig.2D-F IC50(total RNA 48h)=92.93; IC50(total RNA 72h)=91.56) and also the genomic viral RNA (Fig.2G-I; IC50(total RNA 48h)=17.01; IC50(total RNA 72h)=7.412) were significantly reduced by 49% and 42% on average, respectively. Treatment with 1000 nM icatibant for 48 hours led to a reduction of the total SARS-CoV-2 RNA (Fig.2D-F) and also of the genomic SARS-CoV-2 RNA (Fig.2G-I) by 69% and 56% on average, respectively. The genomic viral RNA was detected using RT-qPCR against the sequence of the SARS-CoV-2 RNA-dependent RNA polymerase (RdRP), which is only found in virions as well as during the viral replication. On the other hand, total viral RNA was detected with qPCR targeting a sequence of the SARS-CoV-2 N gene that is present in the viral genome and also in every SARS-CoV-2 protein-encoding transcript. The reduction in total SARS-CoV-2 RNA and genomic viral RNA during treatment with the B2R antagonist was comparable at the indicated concentrations and time points (Fig.2D-I).
3.3 B2 receptor antagonism broadly silences gene expression in bronchial epithelial cells while maintaining cell-intrinsic antiviral response
Severe cases of COVID-19 develop cytokine storms40-42 characterized by excessive systemic release of multiple cytokines including IP-10 (CXCL10), IL-6, IL-8 (CXCL8), and IL-10.43-46 These cases are currently treated with immunomodulating drugs, such as corticosteroids or biologics, like tocilizumab47, though these treatments may interfere with or alter the antiviral immune response. We therefore compared the effect of the B2R antagonist on gene expression of the bronchial epithelium in the light of SARS-CoV-2 infection with the effect of hydrocortisone. While the B2R antagonist mainly suppressed epithelial gene expression during infection, the effects of hydrocortisone on gene induction and gene repression were equal (Fig.3A, Tables S4-5). This finding matches previous reports.48 Therefore, conditions were compared in respect to the antiviral epithelial response. In fact, differentially expressed genes (DEGs) induced by SARS-CoV-2 infection in NHBEs encompassed type-I and -III interferons as well as IFN-inducible and antiviral APOBEC genes (Fig.S1E, Table S6). In particular, SARS-CoV-2 infection induced the antiviral cytidine deaminases APOBEC3A and B, which we previously described to be induced by type-I interferons in the treatment of hepatitis-B virus infection.49 On the other hand, APOBEC3C mRNA levels were decreased in SARS-CoV-2-infected NHBE, which could indicate a novel evasion mechanism.50 Neither the B2R antagonist nor hydrocortisone inhibited the expression of genes with cell-intrinsic antiviral effects and even increased the antiviral factor APOBEC3A at the mRNA level (Fig.3B, Table S7).51
Our gene expression analysis data show that SARS-CoV-2 infection also induces the expression of acute-phase proteins, such as TNF-α and IL-8 (CXCL8),52,53 as well as IL-17C, MIP-3α (CCL20), IL-36γ54,55 and the chemokines CXCL1, -2, -3, -8, -17, CCL2, -3, -554 in primary lung epithelial cells (Fig.3C, Table S8). The induction of these factors most likely contributes to the recruitment and activation of relevant immune cells to the site of infection. Our findings are supported by previous studies of aberrant macrophage and T cell responses underlying immunopathogenesis in bronchoalveolar lavage fluid from COVID-19 patients.56 In addition, the gene expression of acute-phase proteins was not significantly affected in airway epithelial cells by the B2R antagonist or hydrocortisone treatment (Fig.3C, Table S8). Neither drug interfered with canonical cellular antiviral – and reaction-triggering response mechanisms, showing great potential for treatment options of COVID-19 while maintaining the host’s antiviral immune response.
In addition, we found that SARS-CoV-2 infection increases the expression of three known and postulated entry (co-)receptors: 1) the transmembrane serine protease TMPRSS11A (Fig.S1C, Tables S6,9-13), which was described to prime the MERS coronavirus spike protein57, 2) the transmembrane serine protease TMPRSS11D, which was shown to activate SARS-CoV-2 spike protein58 and 3) the pathogen-associated molecular pattern-binding C-type lectin receptor DC-SIGN (CD209), which was described to serve as entry receptor for SARS-CoV59 and has been suggested to act as a receptor also for SARS-CoV-2. The induction of these additional entry receptor candidates triggered by SARS-CoV-2 infection may potentiate the viral spread in the bronchial epithelium and thus represent a pathogenetic approach that needs further research. Overall, treatment with the B2R antagonist and hydrocortisone had no significant effects on the expression of these candidate viral entry receptors (Fig.3D, Table S14). On the other hand, hydrocortisone enhanced the expression of TMPRSS proteases (Fig.3D). In particular, when focusing on the known SARS-CoV-2 entry receptors, hydrocortisone treatment of uninfected cells was already sufficient to induce an increase in TMPRSS2 gene expression (Fig.3E). SARS-CoV-2 infection per se also increased TMPRSS2 expression, and pre-treatment of SARS-CoV-2-infected NHBEs with hydrocortisone further potentiated this effect. On the other hand, ACE2 expression showed only a slight upward trend after hydrocortisone pretreatment (Fig.S2B). Finally, the hydrocortisone pre-treatment of SARS-CoV-2-infected NHBEs had no inhibitory effect on the release of infectious particles 24 hours after infection (Fig.3F), which was expected since the treatment of COVID-19 patients with corticosteroids has an immunomodulatory rationale.
3.4 B2 receptor antagonist counter-balances virus-induced gene expression, particularly genes involved in G protein-coupled receptor (GPCR) signaling and ion transport
With regard to the genes that are attenuated at the mRNA level by B2R antagonism, the DEGs were analyzed in a network analysis using the database string to identify enriched cellular processes. B2R antagonism reduced the expression levels of 343 membrane-bound receptors significantly in treated versus untreated SARS-CoV-2-infected NHBEs (Table S15). Two particular cellular processes affected by pre-treatment with the B2R antagonist were identified, namely G protein-coupled receptor signaling (GO:0007186; Fig.4A, S2C, Tables S4,S17-18) and ion transport (GO:0006811; Fig.4B, Tables S4,17-18). DEGs involved in both processes were significantly downregulated in treated versus untreated SARS-CoV-2-infected NHBEs (Tables 16-18). Notably, all 35 cell surface receptors induced by SARS-CoV-2 infection were downregulated in cells that were treated with the B2R antagonist (Fig.4C,D, Tables S19-20).
4 DISCUSSION
In this study, we provide evidence for the effect of interference with the KKS at the kinin B2 receptor level as a means of protecting the airway epithelium from SARS-CoV-2 infection, while maintaining canonical cell-intrinsic antiviral response.
We initially hypothesized that through KKS interference, either feedback mechanisms or modulated signal transduction target the virus entry receptor ACE2 and thus interfere with the spread of SARS-CoV-2. To this end, the approved B2R antagonist icatibant was used in this study. Here, we demonstrate that treatment with a B2R antagonist inhibits the replication and spread of SARS-CoV-2 in primary airway epithelial cells, which was determined by a decrease in total and genomic SARS-CoV-2 RNA, resulting in less infectious particles in plaque assays, both when applied pre- and post-infection. While a low concentration of 1 nM B2R antagonist was sufficient to reduce viral RNA in primary bronchial epithelial cells when cells were treated pre-infection, 100 nM B2R antagonist was required to this effect, when cells were treated post-infection. In addition, the significant reduction in virus load as determined by PCR tapered off after 96 hours. On the one hand, in vitro infections are performed with excess amounts of virus particles. On the other hand, the fact that, due to its constitution as a peptide analog, the B2R antagonist icatibant used in this study has a short half-life in the human body39 but also pharmacological tolerance to interference at receptor level may explain why the effect reached significance after six hours but did not persist. Therefore, a higher dose of the B2R antagonist may be required at even shorter repetitive dosing intervals to inhibit virus replication in the long term. Therapeutic application in future dose finding studies should therefore focus on early intervention with at least two doses daily60 and on either optimized pharmacokinetics or increased high local tissue concentrations, e.g. through topical application.
Two potential mechanisms of action for suppressing SARS-CoV-2 replication and spread in airway epithelium are revealed by the current study:
1) Treatment with the B2R antagonist led to a downregulation of the viral entry receptor ACE2, in vitro in primary airway epithelial cells and in vivo in a murine airway inflammation model. Since the decrease of genomic SARS-CoV-2 RNA and total SARS-CoV-2 RNA was comparable, we conclude that the B2R antagonist icatibant does probably not affect the viral transcription machinery but inhibits the infection rather on the levels of entry, protein synthesis/processing and assembly, maturation or budding.
In comparison, the corticosteroid hydrocortisone even upregulated TMPRSS2 in infected airway epithelial cells. It is noteworthy that hydrocortisone did not change the release of infectious particles from infected airway epithelial cells into the supernatant. Although TMPRSS2 expression was even enhanced by hydrocortisone, our data implicate that this effect on TMPRSS2 alone is insufficient to increase susceptibility for SARS-CoV-2 infection.
2) Treatment with the B2R antagonist had a broad suppressive effect on gene expression of multiple cell signaling molecules, in particular on membrane-standing factors involved in GPCR signaling and ion transport.
It has recently been published that SARS-CoV-2 may use cellular GPCR signaling pathways, thereby modulate epithelial transport mechanisms involved in ion transport and thereby cause a local ion imbalance in the airways.61 In addition, an extensive recent study described that intracellular SARS-CoV-2 protein interactions include factors involved in intracellular trafficking and transport, particularly ion transport and solute carrier transport.62 In fact, the SARS-CoV-2 infection led to a differential regulation of the gene expression of 12 potassium channel (5 upregulated / 7 downregulated), 1 sodium channel (down), but in particular of 55 members of the solute carrier family (24 downregulated / 31 upregulated) in primary airway epithelial cells. On the other hand, B2R antagonist treatment of SARS-CoV-2-infected NHBE resulted in a downregulation of 20 potassium channel genes and 6 sodium channel genes, as well as a downregulation of 29 members of the solute carrier family.
We therefore conclude that B2R antagonism not only impedes the viral entry process by reducing ACE2, as we had hypothesized, but also counter-regulates cellular processes that include GPCR signaling and transmembrane ion transport, which SARS-CoV-2 may utilize for efficient replication and viral spread.
In conclusion, the results of this study suggest that B2 receptor-antagonism protects airway epithelial cells from SARS-CoV-2 spread by reducing ACE2 levels and by interfering with several cellular signaling processes. Further research is needed to elucidate more details about molecular mechanisms involved in the viral life cycle that kinin B2 receptor antagonism targets and underlie its effects against SARS-CoV-2 infection. Based on these data, we speculate that the protective effects of B2R antagonism could potentially prevent the early stages of COVID-19 from progressing into severe acute respiratory distress syndrome (ARDS) with structural airway damage and fibrotic changes. We therefore propose that the safe approved B2R antagonist icatibant be tested in clinical trials for two important aspects: 1) Treatment of early COVID-19 disease targeting the replication and spread of the virus. 2) Optimized dosage regimen to reflect pharmacokinetics and possible pharmacological tolerance at the receptor level. Future controlled clinical trials must provide substantial evidence for optimal dosage regimen, application, efficacy, and safety to investigate, whether KKS interference at the kinin B2 receptor level can prevent the escalation of COVID-19 to ARDS and long-term lung damage.
Data Availability
All data are provided in the supplemental tables.
Footnotes
Conflict of interests: Dr. Jakwerth reports grants from Federal Ministry of Education and Research, grants from European Institute of Innovation & Technology (EIT), during the conduct of the study. Mr. Feuerherd reports personal fees from Helmholtz Zentrum München and Dr. Höhnle AG, outside the submitted work. Dr. Spinner reports grants, personal fees, non-financial support and other from AbbVie, grants, personal fees, non-financial support and other from Apeiron, personal fees from Formycon, grants, personal fees, non-financial support and other from Gilead Sciences, grants, personal fees and other from Eli Lilly, grants, personal fees, non-financial support and other from Janssen-Cilag, grants, personal fees, non-financial support and other from GSK/ViiV Healthcare, grants, personal fees, non-financial support and other from MSD, outside the submitted work. Prof. Dr. Buch reports personal fees from Virometix AG, other from Virometix AG, other from Trials24 GmbH, other from Clemedi AG, outside the submitted work. Prof. Dr. Protzer reports grants from the Federal Ministry of Education and Research, the German Center for Infection Research (DZIF), the German Research Foundation (DFG), the European Union via Horizon 2020 and the Bavarian Research Foundation during conduct of the study. She receives personal fees as an ad hoc scientific advisor from Abbvie, Arbutus, Gilead, GSK, Johnson & Johnson, Vaccitech. Prof. Dr. Schmidt-Weber reports grants from German Center for Lung Research (DZL), grants from Comprehensive Pulmonary Lung Center (CPC) Munich during the conduct of the study. Personal Fees from Allergopharma and Bencard, outside the submitted work. Dr. Zissler reports grants from Federal Ministry of Education and Research, during the conduct of the study. Dr. Chaker reports grants for clinical studies and research and other from Allergopharma, ALK Abello, AstraZeneca, Bencard / Allergen Therapeutics, ASIT Biotech, Lofarma, GSK, Novartis, LETI, Inmunotek, Roche, Sanofi Genzyme, Zeller and from the European Institute of Technology (EIT); has received travel support from the European Academy of Allergy and Clinical Immunology (EAACI), DGAKI, all outside the submitted work. In addition, Drs. Jakwerth, Feuerherd, Protzer, Schmidt-Weber, Zissler and Chaker are named as inventors on the patent application ‘Novel approaches for treatment of SARS-CoV2-Infection in a patient’. Mr. Guerth, Ms. Oelsner, Dr. Schellhammer, Ms. Giglberger, Ms. Pechtold, Dr. Jerin, Ms. Kugler, Dr. Mogler, Dr. Haller, Ms. Erb, Prof. Dr. Wollenberg have nothing to disclose.
Funding: This study was supported by funding from the German Center of Lung Research (DZL), the Comprehensive Pneumology Center (CPC) Munich, the German Research Foundation (DFG; 398577603, TR22), and the Federal Ministry of Education and Research (ESCAPE; 01KI20169A).
Abbreviations
- ACE2
- angiotensin-converting enzyme 2
- ant-B2R
- kinin B2 receptor antagonist
- BDKRB1
- kinin B1 receptor (gene name)
- BDKRB2
- kinin B2 receptor (gene name)
- B1R
- kinin B1 receptor
- B2R
- kinin B2 receptor
- B2R antagonist
- kinin B2 receptor antagonist
- CAS
- contact activation system
- COVID-19
- coronavirus disease of 2019
- DABK
- des-Arg9-bradykinin
- GPCR
- G protein-coupled receptor
- HC
- hydrocortisone
- HMW-kininogen
- high-molecular-weight-kininogen
- IC50
- half maximal inhibitory concentration
- KKS
- kinin-kallikrein system
- LDH
- lactate dehydrogenase
- NHBE
- normal human bronchial epithelial cells
- RAS
- renin-angiotensin system
- SARS-CoV-2
- Severe Acute Respiratory Syndrome Coronavirus-2
- TMPRSS
- transmembrane serine protease